Indegene Announces Strategic Collaboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate Business Impact
11 July 2024 - 4:56PM
Indegene today announced a strategic collaboration with Microsoft
to empower global life sciences companies to scale up the adoption
of purpose-built, enterprise-grade Generative AI (GenAI) services,
thereby driving faster innovation at scale.
Indegene and Microsoft have committed to
developing resources in highly specialized and skilled medical and
technology tools to co-innovate generative AI services and
workflows across commercial, medical, regulatory, and clinical
functions.
“GenAI presents a once-in-a-decade opportunity
for life sciences companies to modernize business processes and
reimagine the effectiveness and efficiency of their operations
throughout the value chain. Using GenAI, we’re closely working with
many of our clients to solve specific business problems, with
nearly 50 real-world use cases already in an advanced pilot stage,”
said Tarun Mathur, CTO, Indegene. “As we double down on efforts to
strengthen our innovation prowess, we will keep exploring
opportunities for greater collaboration with key technology
providers. We remain focused on helping our clients harness the
potential of GenAI with targeted solutions to address some of their
most pressing operational challenges and make their business
future-ready.”
Alok Lall, Chief Operating Officer, Microsoft
India & South Asia, said, “Generative AI is profoundly shaping
every industry, including life sciences, by offering unprecedented
avenues for healthcare technology advancements. According to a
Microsoft-commissioned study conducted by IDCi, a staggering 79% of
healthcare organizations have now embraced AI. This demonstrates
that the tangible business value of this transformation is
indisputable. By seamlessly integrating Indegene's domain knowledge
with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand
at the forefront of advancing generative AI within the life
sciences sector. This collaborative effort empowers life sciences
companies to fully harness AI's capabilities, fostering innovation
and scalability within the industry.”
Some of the key use cases the strategic
collaboration focuses on in the first phase, include:
- Content
Super App: Using Azure OpenAI Service, the modular content
value chain simplifies content creation and tagging for life
sciences companies. This integrated approach offers a holistic view
of the content value chain, enabling greater velocity, personalized
content, and adoption of new conversation form factors. It also
streamlines creative and video transformation while effectively
engaging healthcare professionals (HCPs), patients and payers
-
Future-ready medical content value chain:
Generative AI capabilities are revolutionizing the medical content
value chain. From sourcing content from relevant literature
articles to authoring core documents such as Clinical Study Reports
(CSRs) and Protocols, Indegene’s solutions accelerate authoring
processes and help ensure compliance across clinical and regulatory
domains
- Data
Management and Analytics for Clinical Trials: Using
Microsoft Fabric, Indegene’s solutions enhance the process of data
ingestion and refinement, facilitate effortless reporting, and
guarantee governance. This leads to proficient analytics, adherence
to compliance, and nimbleness in business operations. It
revolutionizes the way sales users work and provides a competitive
advantage in the marketplace
Indegene counts 20 of the world’s top 20
biopharma companies among its clients. The company brings a
practitioner’s perspective to enable organizations to become
AI-powered companies. With patients and their health outcomes being
the key, Indegene powers clients' ambition with a practitioner’s
expertise in leveraging GenAI, at scale. “With a focus on the right
use cases, a responsible and compliant approach to scaling up, and
shared learnings, we put generative AI to work for our clients,”
added Tarun.
To develop a future-ready workforce, Indegene
has also instituted the ‘GenAI @ Work’ initiative, where all its
5,000+ employees will be trained on various facets of GenAI to
enhance automation and productivity, allowing its employees to
focus on higher-value tasks. As part of this initiative, Indegene
has deployed Microsoft Copilot in several of its core business
processes and has already started seeing significant productivity
improvements.
About Indegene
Indegene Limited (BSE: 544172, NSE: INDGN) is a
digital-first, life sciences commercialization
company. It helps biopharmaceutical, emerging biotech,
and medical device companies develop products, get them to the
market, and grow their impact through the life cycle in a more
effective, efficient, and modern way. Indegene brings
together healthcare domain expertise, fit-for-purpose
technology, and an agile operating model to provide a
diverse range of solutions. These aim to deliver, amongst other
outcomes, a personalized, scalable, and omnichannel experience
for patients and physicians. It’s what drives Indegene’s team and
their purpose to enable healthcare organizations to be
future-ready. To learn more, please visit www.indegene.com
For media inquiries, please
contact:
Indegene | Yadunandan K V
| yadunandan.kv@indegene.com
___________________________________
i The Business Opportunity of AI | Microsoft AI - IDC InfoBrief,
sponsored by Microsoft, The Business Opportunity of AI: How Leading
Organizations Around the World Are Using AI to Drive Impact Across
Every Industry, IDC #US51364223, Nov. 2023.